8
Participants
Start Date
September 24, 2018
Primary Completion Date
March 21, 2019
Study Completion Date
April 21, 2019
PF-06412562
PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
Standard of Care Placebo
25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
Penn State Milton S. Hershey Medical Center, Hershey
Collaborators (1)
Pfizer
INDUSTRY
Milton S. Hershey Medical Center
OTHER